279 related articles for article (PubMed ID: 23718301)
21. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET/CT in lymphoma.
Juweid ME
Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
[TBL] [Abstract][Full Text] [Related]
23. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.
Schiepers C; Filmont JE; Czernin J
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S82-8. PubMed ID: 12719922
[TBL] [Abstract][Full Text] [Related]
24. PET scanning and prognosis in Hodgkin's lymphoma.
Brepoels L; Stroobants S
Curr Opin Oncol; 2008 Sep; 20(5):509-16. PubMed ID: 19106652
[TBL] [Abstract][Full Text] [Related]
25. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
26. The role of PET imaging in lymphoma.
Burton C; Ell P; Linch D
Br J Haematol; 2004 Sep; 126(6):772-84. PubMed ID: 15352980
[TBL] [Abstract][Full Text] [Related]
27. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
[TBL] [Abstract][Full Text] [Related]
28. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
Sioka C
Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
[TBL] [Abstract][Full Text] [Related]
29. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
Adams HJ; Kwee TC
Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
[TBL] [Abstract][Full Text] [Related]
30. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
[TBL] [Abstract][Full Text] [Related]
31. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
[TBL] [Abstract][Full Text] [Related]
32.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
33. Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET.
Fanti S; Castellucci P; Stefoni V; Nanni C; Tani M; Rubello D; Ambrosini V; Zinzani PL; Franchi R
Ann Nucl Med; 2008 Jun; 22(5):429-32. PubMed ID: 18600422
[TBL] [Abstract][Full Text] [Related]
34. The role of FDG-PET scanning in assessing lymphoma in 2012.
Bodet-Milin C; Eugène T; Gastinne T; Bailly C; Le Gouill S; Dupas B; Kraeber-Bodéré F
Diagn Interv Imaging; 2013 Feb; 94(2):158-68. PubMed ID: 23295044
[TBL] [Abstract][Full Text] [Related]
35. Overview of early response assessment in lymphoma with FDG-PET.
MacManus MP; Seymour JF; Hicks RJ
Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
[TBL] [Abstract][Full Text] [Related]
36. Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas.
Spaccarelli N; Gharavi M; Saboury B; Cheng G; Rook AH; Alavi A
Hell J Nucl Med; 2014; 17(2):78-84. PubMed ID: 24997076
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography for detection and staging of malignant lymphoma.
Buchmann I; Moog F; Schirrmeister H; Reske SN
Recent Results Cancer Res; 2000; 156():78-89. PubMed ID: 10802866
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Aug; 170(3):356-66. PubMed ID: 25868485
[TBL] [Abstract][Full Text] [Related]
39. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
Kumar R; Maillard I; Schuster SJ; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
[TBL] [Abstract][Full Text] [Related]
40. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]